https://doi.org/10.5812/jjm.14551

Detection of Helicobacter Pylori in Bronchoalveolar Lavage of Patients With Chronic Obstructive Pulmonary Disease by Real Time Polymerase Chain Reaction

authors:

avatar Mitra Samareh Fekri 1 , avatar Seyed Mehdi Hashemi Bajgani 2 , avatar Atefe Rasti 1 , * , avatar Rostam Yazdani 2 , avatar Hamid Reza Mollaie 2

Physiology Research Center (PRC), Kerman University of Medical Sciences, Kerman, IR Iran
Afzalipour Hospital, Kerman University of Medical Sciences, Kerman, IR Iran
Jundishapur Journal of Microbiology: Vol.8, issue 1; e14551
published online: December 7, 2014
article type: Research Article
received: September 2, 2013
revised: January 11, 2014
accepted: January 20, 2014

how to cite: Samareh Fekri M, Hashemi Bajgani S M, Rasti A, Yazdani R, Mollaie H R. Detection of Helicobacter Pylori in Bronchoalveolar Lavage of Patients With Chronic Obstructive Pulmonary Disease by Real Time Polymerase Chain Reaction. Jundishapur J Microbiol. 2015;8(1):e14551. https://doi.org/10.5812/jjm.14551.

Abstract

Background:

Chronic obstructive pulmonary disease (COPD) is one of the most important causes of disability and mortality in the world. Although cigarette smoking and environmental pollutants have been recognized as the major causes of COPD, the role of infection in the pathogenesis and progression of COPD has also been reported.

Objectives:

The aim of the present study was to find the relationship between Helicobacter Pylori infection and COPD through anti H. pylori IgG serology, real time PCR of bronchoalveolar lavage and trans bronchial biopsy urease tests.

Patients and Methods:

This descriptive cross-sectional study was carried out on 60 adults with COPD. After obtaining the patient’s history, physical examination, spirometry and confirmation of COPD diagnosis by pulmonologist, subjects were selected through convenience sampling. In order to determine the severity and prognosis of disease, the global initiative for chronic obstructive lung disease (GOLD) criteria and BODE index were used. Subjects underwent bronchoscopy for obtaining bronchoalveolar lavage (BAL) samples and biopsy was performed. Biopsy and BAL samples were investigated respectively by urease test and real time PCR. Moreover, patients’ serum samples were serologically studied for detection of anti H. pylori IgG.

Results:

Mean age of the participants was 60.65 ± 9.15 years, and 25% were female and 75% were male. The prevalence rate of H. pylori in COPD patients was 10% according to real time PCR, 88.3% according to the serology test and 0% based on the urease test. According to the results of PCR and considering the severity of disease based on the GOLD criteria, from those with a positive PCR, one patient (16.6%) had very severe obstruction, three (50%) had severe obstruction and two patients (33.3%) had moderate obstruction. The relationship between H. pylori presence (based on PCR) and disease severity and prognosis was not statistically significant.

Conclusions:

These findings can justify the hypothesis of direct injury and chronic inflammation via inhalation and aspiration resulting in H. pylori colonization. In fact, it is thought that H. Pylori infection, beside the host genetic vulnerability and other environmental risk factors might make the patient susceptible to COPD or lead to COPD worsening. Although we found H. pylori infection in some patients with COPD, the results of this study, could not explain the pathogenic mechanisms of COPD.

1. Background

Chronic obstructive pulmonary disease (COPD) is one of the most important causes of disability and mortality in the world. It causes physical disability, affects quality of life and causes death. Chronic obstructive pulmonary disease is the fourth cause of death in the United States of America (1). According to the global initiative for chronic obstructive lung disease (GOLD), COPD is defined as a preventable and treatable disease that leads to the narrowing of the airways and is not fully reversible (2). In industrial countries, cigarette smoking and in developing countries, cigarette smoking and environmental pollutants such as floating particles due to cooking in nonstandard environments are the most common causes of COPD (3). In addition to the role of cigarette, environmental pollutants and genetic factors, the role of infections have also been mentioned in the pathogenesis and progression of this disease (4).

Helicobacter pylori is a Gram-negative, microaerophilic bacterium with a slow growing nature. The most important biochemical index of H. pylori is the production of large quantities of urease. This bacterium colonizes the gastric mucosa and causes a long-term immune response and local and systemic inflammation in the host. They affect the gastric mucosa of almost 50% of the world’s population (5-7). Previous studies have provided extensive evidence on the role of H. pylori in chronic gastritis, peptic ulcer, B-cell lymphoma of gastric mucosa associated-lymphoid tissue (MALT) lymphoma and gastric cancer (diffuse, intestinal) (8-10).

Recent studies have shown that there is a relationship between H. pylori infection and extra gastric diseases such as cardiovascular, skin, liver and rheumatic diseases (11, 12). This bacterium is associated with several respiratory diseases such as COPD, bronchiectasis, asthma, lung cancer and lung tuberculosis (13-15). Indeed, before identifying H. pylori, higher incidence of COPD and tuberculosis had been observed in patients with peptic ulcers compared to the normal population (16-20). Release of similar inflammatory cytokines in H. pylori infection and acute COPD attacks has been proved by some studies (16, 17, 21). The probable mechanism for the relationship between H. pylori and lung diseases might be the systemic effect of gastrointestinal peptides (gastrin, somatostatin) and cytokine release or direct injury and chronic inflammation of airways due to aspiration and inhalation. Since the release of inflammatory cytokines including IL1β, IL8 and TNFα is observed in chronic lung diseases and H. pylori eradication causes returning of these cytokines to the normal levels (22), it seems that activation of inflammatory mediators by H. pylori is the pathogenic mechanism of extragastric manifestations of H. pylori infection (22-25).

2. Objectives

The present study was designed to investigate the relationship between H. pylori and COPD via anti H. pylori IgG serology, real-time PCR of bronchoalveolar lavage and transbronchial biopsy urease tests.

4. Results

The mean age of participants was 60.65 ± 9.15 years (age range: 40-86). In total, 15 individuals (25%) were female and 45 (75%) were male. From all participants, 36 (60%) were cigarette smokers and 41 (68.3%) were opium addicts. In regards to the severity of disease based on FEV1, seven patients (11.66%) had mild obstruction, 29 (48.34%) had moderate obstruction, 15 (25%) had severe obstruction and 9 (15%) had very severe obstruction. The prevalence of H. pylori in COPD patients was 10% (6 of 60 patients) based on real-time PCR, 88.3% (53 of 60 patients) based on serology and 0% based on the urease test (Figure 2).

For determining the relationship between H. Pylori (based on urease test) and disease severity, urease tests were obtained from all patients, and the results were negative for all subjects. The relationship between H. pylori (based on serology) and disease severity was also determined based on the GOLD criteria; in the group that were seropositive based on the enzyme linked immunosorbent (ELISA) method, five (9.4%) had mild obstruction, 27 (50.9%) had moderate obstruction, 13 (24.5%) had severe obstruction and eight (15.1%) suffered from very severe obstruction. No significant relationship was found between the presence of H. pylori (based on serology) and disease severity (P = 0.907). The results are shown in Table 2 and Figure 1.

According to the results of real-time PCR and considering the severity of disease based on the GOLD criteria, amongst those with positive PCR results, one patient (16.6%) had very severe obstruction, three (50%) had severe obstruction and two (33.3%) had moderate obstruction. In other patients real-time PCR results were negative. The relationship between presence of H. pylori (based on real-time PCR) and disease severity was not statistically significant (P = 0.808). The results are demonstrated in Table 3 and Figure 1.

In order to increase the accuracy of determining prognosis of the disease, the BODE index was also used. Accordingly, based on PCR, BODE Index of four patients (66.7%) was between three and four, one patient (14.3%) had a score of six and one patient (16.7%) scored eight. Based on seropositivity, BODE score of 38 patients (71.7%) was between three and four, 10 (18.9%) scored from five to six and five (9.4%) scored from seven to nine; a higher BODE Index correlates with an increasing risk of death. No significant relationship was found between H. pylori infection (based on real-time PCR and serology) and BODE index (P = 0.475 and P = 0.695, respectively). The results are shown in Tables 2 and 3.

Based on the urease, serology and real-time PCR tests and logistic regression, no significant relationship was found between H. pylori in COPD patients and variables of age, educational level, cigarette smoking and reflux symptoms. Based on the serology test, logistic regression showed a significant relationship only with dysphagia (P = 0. 035) (Table 1). Moreover, based on real-time PCR of opium addicts, both raw test and logistic regression showed a significant relationship (P = 0.041) (Table 3) (Figure 2).

Table 2.

The Relationship Between Presence of H. pylori in COPD Patients and BODE Index, FEV1 and Other Parameters (Based on Serology)

SerologyCrudeAdjusted
BS.EP Value aORBS.EP Value OR b
BODE index-0.1290.5840.8260.8790.4121.0510.6951.511
FEV10.4950.3590.1671.64-0.070.6090.9070.931
Age-0.0200.0440.6440.980-0.040.0620.4970.957
Cigarette smoking0.0010.0030.8201.0010.000.0030.9151.00
Opium consumption0.1270.8940.8871.130.1390.8860.8761.149
Hoarseness0.3270.9610.7331.381.060.8181.932.90
Heartburn1.361.110.2323.901.690.8860.0565.44
Regurgitation-0.6571.080.5450.5180.0870.8120.9151.09
Dysphasia0.9430.9850.3382.561.760.8400.0355.86
Epigastria pain0.9500.9830.3332.581.430.8270.0834.20

a Based on logistic regression.

bB(Estimated parameter coefficient), SE (Standard Error),OR(Odds Ratio) , FEV1( Forced Expiratory Volume in one second).

Table 3.

The Relationship Between Presence of H. pylori in COPD Patients and BODE Index, FEV1 and Other Parameters (Based on Real Time PCR)

PCRCrudeAdjusted
BS.EP Value aORBS.EP ValueOR
BODE index-0.1290.5840.0820.879-0.0640.9070.4750.052
FEV1-0.2080.4180.6190.812-0.1730.7140.8080.084
Age-0.009-0.0440.8440.991-0.0150.0680.8200.985
Cigarette smoking0.0000.0030.9001.00-0.0010.0030.7880.999
Opium consumption-2.4201.1700.0380.088-2.361.150.0410.094
Hoarseness-0.3511.0300.7331.420.3150.9570.7421.37
Heartburn0.4021.1660.7300.6690.1540.9550.8721.16
Regurgitation-0.8591.0700.4252.36-0.8110.9530.3952.25
Dysphasia0.3891.2600.7580.670.2141.1620.8541.77
Epigastria pain0.5421.1100.6281.710.5750.9620.5501.37

a Based on logistic regression.

Chronic Obstructive Pulmonary Disease Patient Characteristics
Chronic Obstructive Pulmonary Disease Patient Characteristics
Figure 1.

Chronic Obstructive Pulmonary Disease Patient Characteristics

Prevalence of H. pylori in COPD Based on Urease Real Time PCR and Serological Tests
Prevalence of H. pylori in COPD Based on Urease Real Time PCR and Serological Tests
Figure 2.

Prevalence of H. pylori in COPD Based on Urease Real Time PCR and Serological Tests

5. Discussion

In the present study, bronchoalveolar fluid of 10% of COPD patients was positive for H. pylori according to real time PCR and 88.3% of patients had positive results according to their serology test. Urease test results were negative for all patients. However, there was no significant relationship between the obtained results and the severity and prognosis of COPD based on the GOLD and BODE index criteria. The relationship between chronic bronchitis and peptic ulcer was determined several years prior to the identification of H. pylori, and the prevalence of chronic bronchitis in patients with peptic ulcer was shown to be two to three times more than the control group (18, 32). In a study performed during 1998, the prevalence of H. pylori seropositivity in patients with chronic bronchitis was more than that of the control group (81.6% vs. 57.9%) (33). A study in Denmark demonstrated an association between H. pylori IgG seropositivity and chronic bronchitis (34). According to this study, the prevalence of H. pylori IgG and CagA protein seropositivity in COPD patients was significantly higher than the control group and there was no significant correlation between seropositivity and pulmonary function test (35). It has also been reported that cases with positive IgG H. pylori antibody are more likely to be among chronic bronchitis patients (36). The findings of these studies are similar to our results.

In another previous study, Anti-Cag A level was significantly higher in the COPD group compared to the control group and, similar to our study, no significant relationship was found between H. pylori infection and COPD severity (37). In a study on the relationship between H. pylori infection and pulmonary function based on FEV1 and FVC, lower pulmonary function was reported in seropositive patients, yet after statistical adjustment for socioeconomic status, this relationship disappeared (38). In our study, also, no significant relationship was found between H. pylori seropositivity and pulmonary function tests. Furthermore, in one study that compared non-smoking male patients with non-smoking males without chronic respiratory disease, a strong relationship was found between COPD and H. pylori serology, yet, like our study, no significant relationship was found between H. pylori seropositivity and pulmonary function tests (39). According to a study on the serum of 49 patients with chronic obstructive pulmonary disease, H. pylori IgG level in COPD patients was significantly higher than the control group and there was a significant correlation between the severity of the disease and H. pylori seropositivity (13). The rate of H. pylori seropositivity in our patients was 88.3% and there was no significant correlation between the severity of the disease and seropositivity; the difference between our and the previous study might be due to different sample sizes. A recent study showed that both peptic ulcer and positive H. pylori serology in COPD patients are more than the control group (40).

There are very limited studies that have performed a direct isolation of this bacterium from lung tissue. In one of the previous studies, 34 patients with various types of lung diseases underwent bronchoscopy and biopsy of lung tissue. Histopathology and urease test showed no positive evidence of H. pylori presence in biopsy samples (41). Similarly, in the present study, none of the urease tests were found positive in regards to H. pylori. In some previous studies on patients with bronchiectasis, BAL and lung tissue were investigated by PCR for the presence of H. pylori and, DNA of this bacterium was not found in any of the samples (42, 43). However, in the present study, the real-time PCR detected DNA of H. pylori bacterium in BAL of 10% of COPD patients.

All previous studies have been based on serological tests, however there are several intervening factors that affect the performance of these tests. Moreover, Iran is among regions with high prevalence of H. pylori and approximately 90% of adults in Iran are infected with this bacterium (44). In addition, factors such as age, sex and socioeconomic conditions are involved in COPD and H. pylori infection. Therefore, socioeconomic status should surely be considered in this regard. Indeed, cigarette smoking is also an intervening factor and is one of the major causes of COPD. In regards to the relationship between H. pylori infection and cigarette smoking, there are controversies amongst previous findings (15, 37). In the present study, there was no significant relationship between cigarette smoking and H. pylori in COPD patients.

5.1. Study Limitations

Chronic obstructive pulmonary disease patients, due to sputum production and many gastrointestinal problems frequently use antibiotics and anti-acids and since consumption of these medicines can affect the study results, they should be considered as part of patient’s history. Further studies with a greater sample size and more severe cases of COPD are recommended, because in studies with more severe COPD patients, the number of positive cases in PCR might be higher, as the present study, revealed that positive cases in real time PCR were those with more severe COPD. Another limitation of the present study was the lack of a control group, yet since bronchoscopy is an invasive method, including a control group was ethically impossible.

In the present study, DNA of H. pylori was detected in about 10% of COPD patients by BAL real time PCR and 88.3% of patients were IgG seropositive. As previously mentioned, most previous studies had been based on serology. However, in the present study, in addition to serological tests, real time PCR was applied. The findings can explain the hypothesis of direct injury and chronic inflammation through inhalation and aspiration in addition to systemic immune response resulted from H. pylori colonization.

In fact, it is thought that H. pylori along with the host genetic susceptibility and other environmental risk factors can make the person susceptible to COPD occurrence or lead to COPD worsening. Although we found H. pylori infection in some patients with chronic obstructive pulmonary disease, the results of this study, could not explain the pathogenic mechanisms in chronic obstructive pulmonary disease. It is recommended for other researches to measure inflammatory factors such as IL-1, INFγ and IL8 in BAL of COPD patients who are H. pylori positive based on real time PCR of BAL, in order to identify pathogenic mechanisms of the relationship of this bacterium with COPD. Indeed, studies on genetic loci, through identifying human leukocyte antigens (HLAs), which can make the individual vulnerable to both H. pylori infection and COPD, are recommended.

References

  • 1.

    Buist AS, McBurnie MA, Vollmer WM, Gillespie S, Burney P, Mannino DM, et al. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet. 2007;370(9589):741-50. [PubMed ID: 17765523]. https://doi.org/10.1016/S0140-6736(07)61377-4.

  • 2.

    Committee GE. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2009.

  • 3.

    Dennis RJ, Maldonado D, Norman S, Baena E, Martinez G. Woodsmoke exposure and risk for obstructive airways disease among women. Chest. 1996;109(1):115-9. [PubMed ID: 8549171].

  • 4.

    Pauwels RA, Buist AS, Ma P, Jenkins CR, Hurd SS, Gold Scientific Committee. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: National Heart, Lung, and Blood Institute and World Health Organization Global Initiative for Chronic Obstructive Lung Disease (GOLD): executive summary. Respir Care. 2001;46(8):798-825. [PubMed ID: 11463370].

  • 5.

    Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol. 1996;20(10):1161-81. [PubMed ID: 8827022].

  • 6.

    Mitchell H, Megraud F. Epidemiology and diagnosis of Helicobacter pylori infection. Helicobacter. 2002;7 Suppl 1:8-16. [PubMed ID: 12197904].

  • 7.

    Blaser MJ. Helicobacter pylori and other gastric Helicobacter species. In: Mandell GL, Dolin JR, Bennett R, editors. Principles and Practice of Infectious Diseases. Philadelphia: Churchill Livingstone; 2010. p. 2803-13.

  • 8.

    Cohen H. Peptic Ulcer and Helicobacter Pylori. GastroenterolClin North Am. 2000;29(4):775-89. https://doi.org/10.1016/s0889-8553(05)70146-1.

  • 9.

    Parsonnet J, Hansen S, Rodriguez L, Gelb AB, Warnke RA, Jellum E, et al. Helicobacter pylori infection and gastric lymphoma. N Engl J Med. 1994;330(18):1267-71. [PubMed ID: 8145781]. https://doi.org/10.1056/NEJM199405053301803.

  • 10.

    Xue FB, Xu YY, Wan Y, Pan BR, Ren J, Fan DM. Association of H. pylori infection with gastric carcinoma: a Meta analysis. World J Gastroenterol. 2001;7(6):801-4. [PubMed ID: 11854905].

  • 11.

    Sherman PM, Lin FY. Extradigestive manifestation of Helicobacter pylori infection in children and adolescents. Can J Gastroenterol. 2005;19(7):421-4. [PubMed ID: 16010304].

  • 12.

    De Koster E, De Bruyne I, Langlet P, Deltenre M. Evidence based medicine and extradigestive manifestations of Helicobacter pylori. Acta Gastroenterol Belg. 2000;63(4):388-92. [PubMed ID: 11233523].

  • 13.

    Gencer M, Ceylan E, Yildiz Zeyrek F, Aksoy N. Helicobacter pylori seroprevalence in patients with chronic obstructive pulmonary disease and its relation to pulmonary function tests. Respiration. 2007;74(2):170-5. [PubMed ID: 16369121]. https://doi.org/10.1159/000090158.

  • 14.

    Roussos A, Philippou N, Mantzaris GJ, Gourgoulianis KI. Respiratory diseases and Helicobacter pylori infection: is there a link? Respiration. 2006;73(5):708-14. [PubMed ID: 16763382]. https://doi.org/10.1159/000093816.

  • 15.

    Malfertheiner MV, Kandulski A, Schreiber J, Malfertheiner P. Helicobacter pylori infection and the respiratory system: a systematic review of the literature. Digestion. 2011;84(3):212-20. [PubMed ID: 21757913]. https://doi.org/10.1159/000329351.

  • 16.

    Nelson S, Summer WR, Mason CM. The role of the inflammatory response in chronic bronchitis: therapeutic implications. Semin Respir Infect. 2000;15(1):24-31. [PubMed ID: 10749547].

  • 17.

    Silva JR, Jones JA, Cole PJ, Poulter LW. The immunological component of the cellular inflammatory infiltrate in bronchiectasis. Thorax. 1989;44(8):668-73. [PubMed ID: 2678579].

  • 18.

    Kellow JE, Tao Z, Piper DW. Ventilatory function in chronic peptic ulcer. A controlled study of ventilatory function in patients with gastric and duodenal ulcer. Gastroenterology. 1986;91(3):590-5. [PubMed ID: 3525314].

  • 19.

    Lundegardh G, Helmick C, Zack M, Adami HO. Mortality among patients with partial gastrectomy for benign ulcer disease. Dig Dis Sci. 1994;39(2):340-6. [PubMed ID: 8313816].

  • 20.

    Huang SL, Su CH, Chang SC. Tumor necrosis factor-alpha gene polymorphism in chronic bronchitis. Am J Respir Crit Care Med. 1997;156(5):1436-9. [PubMed ID: 9372657]. https://doi.org/10.1164/ajrccm.156.5.9609138.

  • 21.

    Keatings VM, Collins PD, Scott DM, Barnes PJ. Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med. 1996;153(2):530-4. [PubMed ID: 8564092]. https://doi.org/10.1164/ajrccm.153.2.8564092.

  • 22.

    Kountouras J, Boura P, Lygidakis NJ. Omeprazole and regulation of cytokine profile in Helicobacter pylori-infected patients with duodenal ulcer disease. Hepatogastroenterology. 2000;47(35):1301-4. [PubMed ID: 11100337].

  • 23.

    Mitz HS, Farber SS. Demonstration of Helicobacter pylori in tracheal secretions. J Am Osteopath Assoc. 1993;93(1):87-91. [PubMed ID: 8423130].

  • 24.

    Mehmet N, Refik M, Harputluoglu M, Ersoy Y, Aydin NE, Yildirim B. Serum and gastric fluid levels of cytokines and nitrates in gastric diseases infected with Helicobacter pylori. New Microbiol. 2004;27(2):139-48. [PubMed ID: 15164624].

  • 25.

    Romero Adriàn T, Leal Montiel J. Helicobacter pylori Infection: Regulatory T Cells and Their Participation in the Immune Response. Jundishapur J Microbiol. 2013;6(4):5183. https://doi.org/10.5812/jjm.5183.

  • 26.

    Cote CG, Pinto-Plata VM, Marin JM, Nekach H, Dordelly LJ, Celli BR. The modified BODE index: validation with mortality in COPD. Eur Respir J. 2008;32(5):1269-74. [PubMed ID: 18579541]. https://doi.org/10.1183/09031936.00138507.

  • 27.

    Celli BR, Cote CG, Marin JM, Casanova C, Montes de Oca M, Mendez RA, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med. 2004;350(10):1005-12. [PubMed ID: 14999112]. https://doi.org/10.1056/NEJMoa021322.

  • 28.

    Jones R, Junghard O, Dent J, Vakil N, Halling K, Wernersson B, et al. Development of the GerdQ, a tool for the diagnosis and management of gastro-oesophageal reflux disease in primary care. Aliment Pharmacol Ther. 2009;30(10):1030-8. [PubMed ID: 19737151]. https://doi.org/10.1111/j.1365-2036.2009.04142.x.

  • 29.

    He Q, Wang JP, Osato M, Lachman LB. Real-time quantitative PCR for detection of Helicobacter pylori. J Clin Microbiol. 2002;40(10):3720-8. [PubMed ID: 12354871].

  • 30.

    Kobayashi D, Eishi Y, Ohkusa T, Suzuki T, Minami J, et al. Gastric mucosal density of Helicobacter pylori estimated by real-time PCR compared with results of urea breath test and histological grading. J Med Microbiol. 2002;51(4):305-11. [PubMed ID: 11926735].

  • 31.

    Rinttila T, Kassinen A, Malinen E, Krogius L, Palva A. Development of an extensive set of 16S rDNA-targeted primers for quantification of pathogenic and indigenous bacteria in faecal samples by real-time PCR. J Appl Microbiol. 2004;97(6):1166-77. [PubMed ID: 15546407]. https://doi.org/10.1111/j.1365-2672.2004.02409.x.

  • 32.

    Arora OP, Kapoor CP, Sobti P. Study of gastroduodenal abnormalities in chronic bronchitis and emphysema. Am J Gastroenterol. 1968;50(4):289-96. [PubMed ID: 5687893].

  • 33.

    Caselli M, Zaffoni E, Ruina M, Sartori S, Trevisani L, Ciaccia A, et al. Helicobacter pylori and chronic bronchitis. Scand J Gastroenterol. 1999;34(8):828-30. [PubMed ID: 10499486].

  • 34.

    Rosenstock SJ, Jorgensen T, Andersen LP, Bonnevie O. Association of Helicobacter pylori infection with lifestyle, chronic disease, body-indices, and age at menarche in Danish adults. Scand J Public Health. 2000;28(1):32-40. [PubMed ID: 10817312].

  • 35.

    Roussos A, Tsimpoukas F, Anastasakou E, Alepopoulou D, Paizis I, Philippou N. Helicobacter pylori seroprevalence in patients with chronic bronchitis. J Gastroenterol. 2002;37(5):332-5. [PubMed ID: 12051531]. https://doi.org/10.1007/s005350200046.

  • 36.

    Kanbay M, Gur G, Akcay S, Yilmaz U. Helicobacter pylori seroprevalence in patients with chronic bronchitis. Respir Med. 2005;99(10):1213-6. [PubMed ID: 16140220]. https://doi.org/10.1016/j.rmed.2005.02.036.

  • 37.

    Hashemi SH, Nadi E, Hajilooi M, Seif-Rabiei MA, Roustaei U. Relationship between Helicobacter pylori infection and chronic obstructive pulmonary disease. Acta Med Iran. 2011;49(11):721-4. [PubMed ID: 22131241].

  • 38.

    Fullerton D, Britton JR, Lewis SA, Pavord ID, McKeever TM, Fogarty AW. Helicobacter pylori and lung function, asthma, atopy and allergic disease--a population-based cross-sectional study in adults. Int J Epidemiol. 2009;38(2):419-26. [PubMed ID: 19109248]. https://doi.org/10.1093/ije/dyn348.

  • 39.

    Minov J, Karadzinska Bislimovska J, Vasilevska K, Risteska Kuc S, Stoleski S, Mijakoski D. Helicobacter Pyloriinfection in never-smoking male patients with chronic obstructive pulmonary disease and its relation to lung function. Am J Immunol. 2012;8(4):146-53. https://doi.org/10.3844/ajisp.2012.146.153.

  • 40.

    Siva R, Birring SS, Berry M, Rowbottom A, Pavord ID. Peptic ulceration, Helicobacter pylori seropositivity and chronic obstructive pulmonary disease. Respirology. 2013;18(4):728-31. [PubMed ID: 23438259]. https://doi.org/10.1111/resp.12075.

  • 41.

    Shams-Hosseini NO, Mousavi SA, Kadivar M, Ahmadipour E, Yazdani R, Moradians V. Helicobacter pylori in patients suffering from pulmonary disease. Tanaffos. 2011;10(1):31-6. [PubMed ID: 25191348].

  • 42.

    Ilvan A, Ozturkeri H, Capraz F, Cermik H, Kunter E. Investigation of Helicobacter pylori in bronchoscopic lung specimens of young male patients with bronchiectasis but without gastrointestinal symptoms. Clin Microbiol Infect. 2004;10(3):257-60. [PubMed ID: 15008949].

  • 43.

    Gulhan M, Ozyilmaz E, Tarhan G, Demirag F, Capan N, Erturk A, et al. Helicobacter pylori in bronchiectasis: a polymerase chain reaction assay in bronchoalveolar lavage fluid and bronchiectatic lung tissue. Arch Med Res. 2007;38(3):317-21. [PubMed ID: 17350482]. https://doi.org/10.1016/j.arcmed.2006.11.010.

  • 44.

    Malekzadeh R, Sotoudeh M, Derakhshan MH, Mikaeli J, Yazdanbod A, Merat S, et al. Prevalence of gastric precancerous lesions in Ardabil, a high incidence province for gastric adenocarcinoma in the northwest of Iran. J Clin Pathol. 2004;57(1):37-42. [PubMed ID: 14693833].